To extend our understanding of the patterns of metastatic progression, we retrieved the clinical details of ROS1+, ALK+ and RET+ NSCLC patients from the “Metastatic NSCLC study” by Jee et al. Here, ALK is linked to non-small cell lung carcinoma.